Tag

Weight Loss Drugs

All articles tagged with #weight loss drugs

science6 days ago•20 min saved

Genes load the dice in obesity, but environment tips the balance

Two recent PLOS Medicine studies show that genetics explain a large portion of how BMI tracks in families (about 79% for mothers and 94% for fathers by age eight), but obesity remains a product of gene–environment interaction. With over 3,000 genetic variants involved, today’s obesogenic environment intensifies genetic risk, and genetic differences may influence how weight‑loss drugs work. The takeaway is that obesity is not fate; biology shapes risk while a healthy environment can mitigate it, and understanding this interplay is key to tackling the obesity epidemic.

via EL PAÍS English|

#bmi #environment #genetics

health11 days ago•20 min saved

Retatrutide’s online boom tests the edges of legality

A Washington Post feature describes how people are buying the weight-loss peptide retatrutide online, highlighting safety concerns and an unclear regulatory status, making it a popular but not clearly legal or regulated consumer option.

via The Washington Post|

#glp-1 #health #legality

health12 days ago•61 min saved

MassHealth ends GLP-1 obesity coverage, affecting thousands statewide

MassHealth will stop covering GLP-1 weight‑loss medications starting Friday, affecting about 22,000 Medicaid beneficiaries (including roughly 2,500 children). Coverage remains for diabetes or obesity with certain medical conditions. The move is projected to save about $15 million but risks weight regain and worsened health for those losing access, leaving some to go without treatment, pay out of pocket, or seek cheaper alternatives; under‑21 coverage remains only with medical necessity.

via The Boston Globe|

#glp-1 #health #masshealth

health-policy13 days ago•7 min saved

Medicare's $50 GLP-1 Plan Targets Seniors, But With Limitations

Medicare launches an 18-month GLP-1 Bridge program outside Part D to offer eligible beneficiaries $50-a-month copays for certain weight‑loss drugs (Foundayo tablets, Wegovy, Zepbound) ending Dec 31, 2027. Eligibility is based on BMI and specific health conditions, and prescriptions can be issued even if the doctor doesn’t take Medicare, but some diabetics and individuals with sleep apnea or fatty liver may still face higher costs under Part D. Medicare covers about $245 of the drug cost minus the $50 copay, potentially leaving a total outlay of up to roughly $900 over 18 months for a participant, with no low-income subsidy. Total taxpayer cost is projected at $1.3 billion to $10 billion depending on uptake. The program could boost access but may strain clinics and lacks long-term funding certainty.

via Bridge Michigan|

#glp-1 #health-policy #medicare

health13 days ago•11 min saved

GLP-1 Weight Drugs May Lower Cancer Risk, But More Proof Is Needed

Early observational studies link GLP-1 receptor agonists—widely used for diabetes and weight loss—with a lower risk of several obesity-related cancers, including breast cancer, with a Penn Medicine study showing a 30–35% lower incidence in users; the proposed benefits may come from weight loss, reduced inflammation, improved insulin sensitivity, and lower estrogen after menopause, and possibly direct anti-cancer effects. However, these findings are not from randomized trials and GLP-1s are not FDA-approved for cancer prevention; safety concerns like medullary thyroid carcinoma warning exist, so for now cancer prevention relies on established screenings and managing metabolic health, with any future preventive use limited to high-risk patients under supervision.

via Health US News|

#breast-cancer #cancer-risk #glp-1-receptor-agonists

health15 days ago•11 min saved

Medicare rolls out temporary obesity-drug coverage via Bridge program with $50 copay

Medicare will temporarily cover obesity GLP-1 medications under the Bridge program starting July 1, with a flat $50 monthly copay for eligible Part D beneficiaries and no deductible contribution toward costs. Drugs like Wegovy and Zepbound are included, and eligibility is based on BMI thresholds and related health conditions; the coverage runs through an 18-month demonstration ending in 2027 unless extended, with prior-authorization handled by providers and Humana. While the move could unlock millions of potential patients for Novo Nordisk and Lilly, concerns include surge in demand, administrative burden, and the uncertain long-term viability beyond the demonstration, as well as ongoing policy debates such as Balance and the Treat and Reduce Obesity Act.

via CNBC|

#bridge-program #glp-1 #health

health15 days ago•11 min saved

Medicare kicks off temporary, discounted obesity-drug coverage for eligible seniors

Medicare will launch the temporary GLP-1 Bridge program on July 1, offering eligible Part D enrollees access to weight-loss drugs (Wegovy, Zepbound, Foundayo) for about $50 a month, subject to BMI and health criteria. The 18-month pilot tests new coverage ahead of a potential Balance model in 2028; costs to Medicare are uncertain and depend on enrollment. While many seniors could benefit, eligibility gaps remain, and questions linger about post-Bridge access and insurer participation. Drugs can be obtained via pharmacies or LillyDirect, and manufacturers say supply is sufficient. The program aims to treat obesity like other diseases and reduce related health risks, though long-term savings are debated.

via CNN|

#bmi #bridge-program #glp-1

health15 days ago•38 min saved

Louisiana researchers probe how GLP-1 weight‑loss drugs reshape metabolism

Louisiana researchers at Pennington Biomedical Center, led by Dr. Eric Ravussin, are studying how GLP-1 weight‑loss drugs affect metabolism and muscle mass, including resting metabolic rate and energy expenditure in a metabolic chamber to understand metabolic adaptation that can slow weight loss, while clinicians emphasize adequate protein and exercise to minimize muscle loss as these therapies evolve.

via The Advocate|

#glp-1-drugs #health #metabolic-adaptation

health21 days ago•5 min saved

Massachusetts cuts coverage for weight-loss drugs, pushing patients to pay out of pocket

MassHealth and the state Group Insurance Commission will stop covering GLP-1 weight-loss drugs starting July 1, affecting about 22,000 people and leaving many low-income patients to shoulder up to roughly $450 per month out of pocket. Some patients are taking second jobs or depleting savings to afford treatment, while doctors warn that restricting access undermines obesity as a disease and may worsen health outcomes. State officials say the policy saves about $15 million annually amid rising drug prices, and even private insurers have reduced coverage; alternatives include switching to less effective medications. The move highlights tensions between access to effective obesity treatments and cost containment, with concerns about equity and long-term health impacts for those on public insurance.

via WBUR|

#glp-1 #health #masshealth

health22 days ago•13 min saved

Biotech Aims to Slim Fat Without Slashing Muscle

A wave of weight-loss drugs seeks to burn fat while preserving or boosting lean muscle, addressing the muscle loss seen with current GLP-1 therapies. Beyond reusing older drugs like bimagrumab, new combos (e.g., CagriSema) and Cambrian Biotech’s ATX-304 show early promise in raising metabolic rate and cutting visceral fat, though findings are preliminary and regulatory or payer hurdles remain. If proven, these approaches could enable body recomposition across broader age groups.

via Business Insider|

#atx-304 #glp-1 #health

health24 days ago•6 min saved

GLP-1 Weight-Loss Drugs May Boost Male Fertility and Hormone Health

A systematic review of five randomized trials suggests GLP-1 weight-loss medications (e.g., semaglutide, liraglutide) may improve testosterone, sperm quality, and reproductive hormones in obese men with low testosterone, largely in the context of weight loss; however, the evidence is limited and larger, targeted studies are needed.

via Fox News|

#glp-1 #health #male-fertility

health27 days ago•6 min saved

Surge in GLP-1 overdoses linked to easy telehealth and unregulated meds

GLP-1 diabetes/weight‑loss drugs are seeing a rise in life‑threatening overdoses as use has surged since 2021 and telehealth lowers barriers to access, sometimes bypassing in-person care. Poison‑control calls jumped from about 100 monthly in 2021 to roughly 1,000 by 2025, with patients suffering severe vomiting, dehydration, seizures, and even vomiting blood. Compounded or online‑sourced versions can have inconsistent dosing and less doctor oversight, prompting FDA warnings about unregulated products. Experts urge caution, proper dosing, and urgent care for severe symptoms, noting risks like pancreatitis and hypoglycemia, with children also at risk.

via New York Post|

#fda-warnings #glp-1 #health

health29 days ago•3 min saved

Medicare's $50 GLP-1 Drug Benefit Sparks Doctor Bottlenecks

Medicare will cover weight-loss drugs for $50/month from July through 2027, a move that could unleash pent-up demand but strain clinics with prior authorizations and essential counseling, while not covering accompanying nutrition or behavioral support or counting toward out-of-pocket caps; uptake may be limited by existing GLP-1 use and fixed incomes.

via Axios|

#glp-1 #health #medicare

health-and-medicine29 days ago•5 min saved

GLP-1 Weight-Loss Drugs Trim Pounds But Also Trim Activity

A study presented at ENDO 2026 analyzed Fitbit data from NIH All of Us and found that adults with obesity who started GLP-1 medications (semaglutide or tirzepatide) lost weight but became less physically active. Average daily steps dropped from 5,047 to 4,487 and moderate-to-vigorous physical activity fell from 28 to 22 minutes per day, with the largest decreases in men and those reporting joint/muscle pain. Age, heart failure, and prior stroke did not change the trend. The researchers stress that exercise should accompany GLP-1 therapy to protect muscle and long-term health, marking the first large wearable-data study of activity in users of these drugs.

via ScienceDaily|

#endo-2026 #fitbit-data #glp-1-receptor-agonists

health1 month ago•3 min saved

GLP-1 Weight-Loss Drugs Linked to Lower Cancer Risk and Mortality in New Studies

At ASCO's annual meeting, several studies suggest GLP-1 weight-loss drugs may reduce cancer risk and improve outcomes: in 110,000 women, a 30% lower incidence of breast cancer; in 27,000 breast cancer patients, a 30% lower risk of death when added to standard treatment; and in 12,000 patients with multiple cancers, a 38–50% lower likelihood of progressing to stage IV. The findings are observational and not yet definitive; more research is needed to determine whether benefits come from weight loss or direct anti-cancer effects, though anti-inflammatory and immune-modulatory mechanisms are plausible.

via The Guardian|

#asco-meeting #breast-cancer #cancer-prevention